Faltas, Bishoy Morris

Publications

Sort by

Co-Author Network

selected publications

Common germline-somatic variant interactions in advanced urothelial cancer. Nature communications. 2020 Academic Article GET IT
Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. Translational oncology. 2020 Academic Article GET IT
Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. European urology. 2020 Review GET IT
Times cited: 1
Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers. Nature communications. 2020 Academic Article GET IT
Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nature reviews. Urology. 2020 Review GET IT
Times cited: 11
A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nature communications. 2020 Academic Article GET IT
Times cited: 10
Pan-cancer analysis of whole genomes. Nature. 2020 Academic Article GET IT
Times cited: 186
The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing. Cancer treatment and research communications. 2020 Academic Article GET IT
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 4
Clinical features of neuroendocrine prostate cancer. European journal of cancer. 2019 Academic Article GET IT
Times cited: 21
Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. Proceedings of the National Academy of Sciences of the United States of America. 2019 Academic Article GET IT
Times cited: 4
Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. JCO precision oncology. 2019 Academic Article GET IT
Times cited: 4
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nature communications. 2019 Academic Article GET IT
Times cited: 29
Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. European urology oncology. 2019 Academic Article GET IT
Times cited: 9
Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2019 Academic Article GET IT
Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma. Expert opinion on therapeutic targets. 2018 Academic Article GET IT
Times cited: 1
The molecular limitations of biomarker research in bladder cancer. World journal of urology. 2018 Academic Article GET IT
Times cited: 13
Treatment resistance in urothelial carcinoma: an evolutionary perspective. Nature reviews. Clinical oncology. 2018 Review GET IT
Times cited: 13
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer. 2018 Academic Article GET IT
Times cited: 34
Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes. Urologic oncology. 2017 Academic Article GET IT
Times cited: 7
Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 18
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine. Cancer discovery. 2017 Academic Article GET IT
Times cited: 271
Immune-checkpoint blockade in cisplatin-ineligible patients with urothelial cancer. Lancet (London, England). 2016 Comment GET IT
Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nature genetics. 2016 Academic Article GET IT
Times cited: 129
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. Urologic oncology. 2016 Academic Article GET IT
Times cited: 12
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urologic oncology. 2016 Review GET IT
Times cited: 26
Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 37
Radical Cystectomy for Bladder Cancer in Patients With and Without a History of Pelvic Irradiation: Survival Outcomes and Diversion-related Complications. Urology. 2015 Academic Article GET IT
Times cited: 9
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA oncology. 2015 Academic Article GET IT
Times cited: 165
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 561
Recurrence patterns after open and robot-assisted radical cystectomy for bladder cancer. European urology. 2015 Academic Article GET IT
Times cited: 101
Novel molecular targets for urothelial carcinoma. Expert opinion on therapeutic targets. 2015 Review GET IT
Times cited: 7
Preexposure prophylaxis with tenofovir or emtricitabine-tenofovir reduces herpes simplex virus type -2 transmission. AIDS Reader. 2014 Article
Efavirenz for initial therapy of HIV associated with increased suicide risk. AIDS Reader. 2014 Article
Optimal timing for starting antiretroviral therapy in HIV-infected patients with cryptococcal meningitis. AIDS Reader. 2014 Article
Immunologics and chemotherapeutics for renal cell carcinoma. Seminars in interventional radiology. 2014 Academic Article GET IT
Times cited: 9
Myelodysplastic syndromes: toward a risk-adapted treatment approach. Expert review of hematology. 2013 Review GET IT
Times cited: 18
Designing and managing modern biobanks. Genetic Engineering and Biotechnology News. 2013 Article GET IT
Sequential occurrence of a splenic marginal zone lymphoma, extranodal MALT lymphoma, and Hodgkin lymphoma. Clinical lymphoma, myeloma & leukemia. 2013 Academic Article GET IT
Times cited: 2
Myelodysplastic syndromes: what do hospitalists need to know?. Journal of hospital medicine. 2013 Academic Article GET IT
Times cited: 17
Sustained remission in a patient with myelodysplastic syndrome and a complex karyotype after erythropoiesis-stimulating therapy followed by colonic T-cell lymphoblastic lymphoma. Leukemia & lymphoma. 2012 Letter GET IT
Times cited: 2
Adult primary pulmonary primitive neuroectodermal tumor: molecular features and translational opportunities. Cancer biology & therapy. 2012 Review GET IT
Times cited: 15
Cornering metastases: therapeutic targeting of circulating tumor cells and stem cells. Frontiers in oncology. 2012 Review GET IT
Times cited: 25
Dabigatran etexilate: what do hospitalists need to know?. Journal of hospital medicine. 2011 Review GET IT
Times cited: 5
Circulating tumor cells in the cerebrospinal fluid: "tapping" into diagnostic and predictive potential. Oncotarget. 2011 Comment GET IT
Times cited: 5
Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Letter GET IT
Times cited: 16
Cancer is an ancient disease: the case for better palaeoepidemiological and molecular studies. Nature reviews. Cancer. 2011 Letter GET IT
Times cited: 9
Mental nerve neuropathy: frequently overlooked clinical sign of hematologic malignancies. The American journal of medicine. 2011 Letter GET IT
Times cited: 6
A new anticoagulant for a new era: review of recent data on dabigatran etexilate. Clinical advances in hematology & oncology : H&O. 2010 Academic Article GET IT
Times cited: 2
Prolonged and increased postoperative risk of venous thromboembolism: rationale for even more 'extended' prophylaxis?. Expert review of hematology. 2010 Article GET IT
Times cited: 1
Targeting hematogenous spread of circulating tumor cells by a chemotactic drug-eluting IVC filter to prevent pulmonary and systemic metastasis. Medical hypotheses. 2009 Academic Article GET IT
Times cited: 5
Update on perioperative bridging in patients on chronic oral anticoagulation. Expert review of cardiovascular therapy. 2009 Review GET IT
Times cited: 6
Gastric Burkitt lymphoma associated with Efalizumab and Helicobacter pylori. Leukemia & lymphoma. 2009 Letter GET IT
Times cited: 1
A case of primary meningococcal pericarditis caused by Neisseria meningitidis serotype Y with rapid evolution into cardiac tamponade. Journal of general internal medicine. 2008 Academic Article GET IT
Times cited: 5
Can't catch a breath. The American journal of medicine. 2007 Comment GET IT
Robotic surgery: applications, limitations, and impact on surgical education. MedGenMed : Medscape general medicine. 2005 Academic Article GET IT
Times cited: 35

more ...

less ...

Research

research overview

https://faltaslab.weill.cornell.edu/research

Sort by

Co-investigator Network

Funding awarded

Immunogenomic determinants of ethnic disparities in clinical outcomes for urothelial cancer patients awarded by New York Genome Center Inc. Principal Investigator 2020 - 2022
APOBEC MUTAGENESIS IN BLADDER CANCER: MECHANISMS AND THERAPEUTIC OPPORTUNITIES awarded by Starr Cancer Consortium Principal Investigator 2019 - 2021
Dissecting the Role of APOBEC3 Mutagenic Proteins as Drivers of Genomic-Instability and Chemotherapy-Resistance in Urothelial Carcinoma awarded by United States Department of Defense Principal Investigator 2017 - 2021

more ...

less ...

Background

education and training

M.B.,B.Ch., College of Medicine Assiut (Egypt) 2004

Contact

full name

Bishoy Morris Faltas

primary email

bmf9003@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Bishoy Morris Faltas Assistant Professor of Medicine

Publications

selected publications

Research

research overview

Funding awarded

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Research

research overview

Funding awarded

Background

education and training

Contact

full name

primary email

webpage